Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13230434 | 1.00 | NAMPT (0.60) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| SCHEMBL13230439 | 1.00 | NAMPT (0.60) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| Hydrochloric Acid SCHEMBL2791710 | 0.99 | NAMPT (0.59) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| Hydrochloric Acid SCHEMBL2790960 | 0.99 | NAMPT (0.59) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| Hydrochloric Acid SCHEMBL27719878 | 0.99 | NAMPT (0.59) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| SCHEMBL2794103 | 0.92 | ROCK2 (0.57) | NAMPTL3MBTL1ROCK2ROCK1KDM4E | |
| SCHEMBL2792952 | 0.91 | HIF1A (0.53) | NAMPTL3MBTL1ROCK2ROCK1KDM4E | |
| SCHEMBL2793989 | 0.90 | NAMPT (0.55) | NAMPTL3MBTL1ROCK2ROCK1KDM4E | |
| SCHEMBL2792068 | 0.89 | NAMPT (0.60) | NAMPTL3MBTL1ROCK2ROCK1CYP3A4 | |
| SCHEMBL2794930 | 0.89 | NAMPT (0.58) | NAMPTL3MBTL1ROCK2ROCK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| CN-101296904-A | Amide derivatives as kinase inhibitors | DEVGEN NV (BE) | 2008-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | NAMPT 1420/4885L3MBTL1 2827/4885ROCK2 528/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | NAMPT 1420/4885L3MBTL1 2827/4885ROCK2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.